A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder

Aimee L. McRae-Clark, Rickey E. Carter, Therese K. Killeen, Matthew J. Carpenter, Kathleen G. White, Kathleen T. Brady

Research output: Contribution to journalArticle

50 Scopus citations

Abstract

This study evaluated the effects of atomoxetine on the symptoms of attention deficit hyperactivity disorder (ADHD) and marijuana use in marijuana-dependent adults. In conjunction with motivational interviewing, participants received either atomoxetine (n = 19) or matching placebo (n = 19) for 12 weeks. Participants randomized to atomoxetine had greater improvement in ADHD on the Clinical Global Impression-Improvement scale than participants treated with placebo. No treatment group differences in self-rated ADHD symptoms, overall Wender-Reimherr Adult Attention Deficit Disorder Scale scores, or marijuana use outcomes were noted. These results suggest that atomoxetine may improve some ADHD symptoms but does not reduce marijuana use in this population.

Original languageEnglish (US)
Pages (from-to)481-489
Number of pages9
JournalAmerican Journal on Addictions
Volume19
Issue number6
DOIs
StatePublished - Nov 2010

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder'. Together they form a unique fingerprint.

  • Cite this